Back to Search
AMITA PATNAIK, M.D.
M.D.
Medical Oncology Physician
NPI: 1538162029IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
L0499(TX)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
OTHER
Class of 1992
Research & Publications (20)
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.
PMID 19633048·Ann Oncol·2010
3-trial
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
PMID 17189413·Clin Cancer Res·2006
3-trial
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
PMID 14581347·Clin Cancer Res·2003
3-trial
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.
PMID 12114414·Clin Cancer Res·2002
3-trial
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
PMID 11099327·J Clin Oncol·2000
3-trial
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.
PMID 19281729·Int J Clin Pharmacol Ther·2009
3-trial
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
PMID 18795291·Cancer Chemother Pharmacol·2009
3-trial
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
PMID 19449006·Cancer Chemother Pharmacol·2009
3-trial
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
PMID 19147780·Clin Cancer Res·2009
3-trial
Effects of collisions on electronic-resonance-enhanced coherent anti-Stokes Raman scattering of nitric oxide.
PMID 19508066·J Chem Phys·2009
8-other
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
PMID 18824702·J Clin Oncol·2008
3-trial
Perturbative theory and modeling of electronic-resonance-enhanced coherent anti-Stokes Raman scattering spectroscopy of nitric oxide.
PMID 18465923·J Chem Phys·2008
8-other
Controlled parametric generation in a double-ladder system via all-resonant four-wave mixing.
PMID 18278117·Opt Lett·2008
8-other
Equilibrium structure and dynamics of (2R, 3R)-(+)-bis(decyloxy)succinic acid at the air-water interface.
PMID 18177056·Langmuir·2008
8-other
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
PMID 18202410·J Clin Oncol·2008
3-trial
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
PMID 18927309·Clin Cancer Res·2008
3-trial
Spatial distribution of orofacial cleft defect births in Harris County, Texas, and radium in the public water supplies: a persistent association?
PMID 19065472·Tex Med·2008
8-other
Unilamellar composite vesicles and Y-junctions from pristine fullerene C(60).
PMID 18802505·Chem Commun (Camb)·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4383 MEDICAL DR
SAN ANTONIO, TX 78229 - Phone
- (210) 593-5700
Quick Facts
- NPI
- 1538162029
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile